UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): December 21, 2005


                                 REMEDENT, INC.
                                 --------------
             (Exact name of registrant as specified in its charter)


           Nevada                         001-15975              86-0837251
           -------                        ---------              ----------
(State or other jurisdiction of    (Commission File Number)   (I.R.S. Employer
incorporation or organization)                               Identification No.)


                           Xavier de Cocklaan 42, 9831
                                 Deurle, Belgium
                                 ---------------
    (Address and telephone number of principal executive offices) (Zip Code)

                                011-329-321-7080
                                ----------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[]   Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[]   Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[]   Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[]   Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))

                                       1
<PAGE>

Section 1 - Registrant's Business and Operations

Item 1.01   Entry into a Material Definitive Agreement.

     On December 21, 2005,  Remedent NV, a wholly-owned  subsidiary of Remedent,
Inc.  (the  "Company")  entered into an Agreement  with Pierre Fabre  Medicament
S.A.,  a  corporation  organized  under  the laws of  France  ("Pierre  Fabre").
Pursuant to the  Agreement,  commencing  on January 1, 2006 Pierre Fabre will be
the Company's sole and exclusive  distributor of the I-White(R) and  MetaTray(R)
products ("Products") in France, Guadeloupe,  Guiana,  Martinique,  Mayotte, New
Caledonia, French Polynesia, La Reunion, St. Bartholomew, St. Martin, St. Pierre
and Miquelon,  Wallis and Futuna.  The Agreement  requires Pierre Fabre to order
minimum  quantities of the Products in accordance to the terms of the Agreement.
In the event that  Pierre  Fabre  fails to sell the  minimum  quantities  of the
Products  within the first  eighteen (18) months of the  Agreement,  the Company
will have a right to terminate  the Agreement on a product by product basis upon
one (1) month prior written notice.

     The term of the  Agreement is for an initial  three (3) years (the "Initial
Term"), unless terminated by either party under the Agreement.  After the end of
the Initial Term,  the Agreement will  automatically  be extended for successive
two (2) year terms  ("Additional  Term")  unless the  Agreement is terminated by
written notice at least six (6) months before the expiration of the Initial Term
or the respective  Additional  Term.  The Agreement  grants Pierre Fabre a first
option right to expand the  territory  under the  Agreement  to include  Cyprus,
Morocco, Tunisia, Algeria and South Africa. In addition, except for relationship
created by the Agreement,  there is no other material  relationship  between the
Company or Pierre Fabre.


                                       2
<PAGE>

                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                            REMEDENT, INC.
                                            a Nevada Corporation


Dated:  December 28, 2005                   /s/ Robin List
                                            ------------------------------------
                                            Robin List, Chief Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "for122105.txt", "secsgml_size_bytes": 4479}]
{"company-data": {"conformed-name": "REMEDENT, INC.", "cik": "0001078037", "assigned-sic": "3843", "irs-number": "860837251", "state-of-incorporation": "NV", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-15975", "film-number": "051288695"}, "business-address": {"street1": "XAVIER DE COCKLAAN 42", "city": "DEURLE", "state": "C9", "zip": "9831", "phone": "011-32-9-321-7090"}, "mail-address": {"street1": "XAVIER DE COCKLAAN 42", "city": "DEURLE", "state": "C9", "zip": "9831"}, "former-company": [{"former-conformed-name": "REMEDENT USA INC", "date-changed": "20050609"}, {"former-conformed-name": "REMEDENT USA INC/AZ", "date-changed": "19991220"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): December 21, 2005

                                 REMEDENT, INC.
                                 --------------
             (Exact name of registrant as specified in its charter)

           Nevada                         001-15975              86-0837251
           -------                        ---------              ----------
(State or other jurisdiction of    (Commission File Number)   (I.R.S. Employer
incorporation or organization)                               Identification No.)

                           Xavier de Cocklaan 42, 9831
                                 Deurle, Belgium
                                 ---------------
    (Address and telephone number of principal executive offices) (Zip Code)

                                011-329-321-7080
                                ----------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[]   Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[]   Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[]   Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[]   Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))

                                       1
Section 1 - Registrant's Business and Operations

Item 1.01   Entry into a Material Definitive Agreement.

     On December 21, 2005,  Remedent NV, a wholly-owned  subsidiary of Remedent,
Inc.  (the  "Company")  entered into an Agreement  with Pierre Fabre  Medicament
S.A.,  a  corporation  organized  under  the laws of  France  ("Pierre  Fabre").
Pursuant to the  Agreement,  commencing  on January 1, 2006 Pierre Fabre will be
the Company's sole and exclusive  distributor of the I-White(R) and  MetaTray(R)
products ("Products") in France, Guadeloupe,  Guiana,  Martinique,  Mayotte, New
Caledonia, French Polynesia, La Reunion, St. Bartholomew, St. Martin, St. Pierre
and Miquelon,  Wallis and Futuna.  The Agreement  requires Pierre Fabre to order
minimum  quantities of the Products in accordance to the terms of the Agreement.
In the event that  Pierre  Fabre  fails to sell the  minimum  quantities  of the
Products  within the first  eighteen (18) months of the  Agreement,  the Company
will have a right to terminate  the Agreement on a product by product basis upon
one (1) month prior written notice.

     The term of the  Agreement is for an initial  three (3) years (the "Initial
Term"), unless terminated by either party under the Agreement.  After the end of
the Initial Term,  the Agreement will  automatically  be extended for successive
two (2) year terms  ("Additional  Term")  unless the  Agreement is terminated by
written notice at least six (6) months before the expiration of the Initial Term
or the respective  Additional  Term.  The Agreement  grants Pierre Fabre a first
option right to expand the  territory  under the  Agreement  to include  Cyprus,
Morocco, Tunisia, Algeria and South Africa. In addition, except for relationship
created by the Agreement,  there is no other material  relationship  between the
Company or Pierre Fabre.

                                       2
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                            REMEDENT, INC.
                                            a Nevada Corporation

Dated:  December 28, 2005                   /s/ Robin List
                                            ------------------------------------
                                            Robin List, Chief Executive Officer